Micropapillary histology a frequent morphology of mutation-associated lung adenocarcinoma?

American Journal of Clinical Pathology

Volumn 131, Issue 5, 2009, Pages 615-617

  Borczuk, Alain C ^a  

^a Department of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; K RAS PROTEIN; PROTEIN TYROSINE KINASE INHIBITOR; TUMOR MARKER;

ADVANCED CANCER; CANCER CLASSIFICATION; CANCER DIAGNOSIS; CANCER SURGERY; CANCER SURVIVAL; CYSTADENOMA; DISEASE CLASSIFICATION; DISEASE SEVERITY; DOWNSTREAM PROCESSING; EDITORIAL; ENZYME ACTIVATION; GENE DELETION; GENE MUTATION; HISTOPATHOLOGY; HUMAN; LUNG ADENOCARCINOMA; LUNG MICROPAPILLARY ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; LYMPH NODE METASTASIS; MEDICAL SOCIETY; METASTASIS; MORPHOLOGY; ONCOGENE K RAS; PAPILLARY CARCINOMA; PATHOLOGIST; PRIORITY JOURNAL; PROGNOSIS; PROTEIN TARGETING; WORLD HEALTH ORGANIZATION; ADENOCARCINOMA; CLASSIFICATION; DIAGNOSTIC PROCEDURE; GENETICS; LUNG TUMOR; MUTATION; NOTE; PATHOLOGY;

ADENOCARCINOMA, PAPILLARY; HUMANS; LUNG NEOPLASMS; MOLECULAR DIAGNOSTIC TECHNIQUES; MUTATION; PROGNOSIS;

EID: 65349086659     PISSN: 00029173     EISSN: None     Source Type: Journal    
DOI: 10.1309/AJCP9NA3YQSWDYUN     Document Type: Editorial

References (22)

1. Achcar RDD, Nikiforova MN, Yousem SA. Micropapillary lung adenocarcinoma: EGFR, K-ras, and BRAF mutational profile. Am J Clin Pathol. 2009;131:694-700.
2. World Health Organization. Pathology and Genetics of Tumours of the Lung, Pleura, Thymus, and Heart. Lyon: IARC Press; 2004.
3. Silver SA, Askin FB. True papillary carcinoma of the lung: a distinct clinicopathologic entity. Am J Surg Pathol. 1997;21:43-51.
4. Roh MS, Lee JI, Choi PJ, et al. Relationship between micropapillary component and micrometastasis in the regional lymph nodes of patients with stage I lung adenocarcinoma. Histopathology. 2004;45:580-586.
5. Kamiya K, Hayashi Y, Douguchi J, et al. Histopathological features and prognostic significance of the micropapillary pattern in lung adenocarcinoma. Mod Pathol. 2008;21:992-1001.
6. Motoi N, Szoke J, Riely GJ, et al. Lung adenocarcinoma: modification of the 2004 WHO mixed subtype to include the major histologic subtype suggests correlations between papillary and micropapillary adenocarcinoma subtypes, EGFR mutations and gene expression analysis. Am J Surg Pathol. 2008;32:810-827.
7. Fukuoka M, Yano S, Giaccone G, et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (the IDEAL1 trial) [corrected]. J Clin Oncol. 2003;21:2237-2246.
8. Miller VA, Kris MG, Shah N, et al. Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer. J Clin Oncol. 2004;22:1103-1109.
9. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004;350:2129-2139.
10. Pao W, Miller V, Zakowski M, et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A. 2004;101:13306-13311.
11. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med. 2005;353:123-132.
12. Toyooka S, Takano T, Kosaka T, et al. Epidermal growth factor receptor mutation, but not sex and smoking, is independently associated with favorable prognosis of gefitinib-treated patients with lung adenocarcinoma. Cancer Sci. 2008;99:303-308.
13. Shigematsu H, Lin L, Takahashi T, et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst 2005;97:339-346.
14. Pao W, Wang TY, Riely GJ, et al. KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med. 2005;2:e17.
15. Ding L, Getz G, Wheeler DA, et al. Somatic mutations affect key pathways in lung adenocarcinoma. Nature. 2008;455:1069-1075.
16. Yang CH, Yu CJ, Shih JY, et al. Specific EGFR mutations predict treatment outcome of stage IIB/IV patients with chemotherapy-naive non-small-cell lung cancer receiving first- line gefitinib monotherapy. J Clin Oncol. 2008;26:2745-2753.
17. Zakowski MF, Hussain S, Pao W, et al. Morphologic features of adenocarcinoma of the lung predictive of response to the epidermal growth factor receptor kinase inhibitors erlotinib and gefitinib. Arch Pathol Lab Med. 2009;133:470-477.
18. Yousem SA, Nikiforova M, Nikiforov Y. The histopathology of BRAF-V600E-mutated lung adenocarcinoma. Am J Surg Pathol. 2008;32:1317-1321.
19. Yatabe Y, Takahashi T, Mitsudomi T. Epidermal growth factor receptor gene amplification is acquired in association with tumor progression of EGFR-mutated lung cancer. Cancer Res. 2008;68:2106-2111.
20. Yoshida Y, Shibata T, Kokubu A, et al. Mutations of the epidermal growth factor receptor gene in atypical adenomatous hyperplasia and bronchioloalveolar carcinoma of the lung. Lung Cancer. 2005;50:1-8.
21. Slebos RJ, Kibbelaar RE, Dalesio O, et al. K-ras oncogene activation as a prognostic marker in adenocarcinoma of the lung. N Engl J Med. 1990;323:561-565.
22. Kim YT, Kim TY, Lee DS, et al. Molecular changes of epidermal growth factor receptor (EGFR) and KRAS and their impact on the clinical outcomes in surgically resected adenocarcinoma of the lung. Lung Cancer. 2008;59:111-118.